MASTINI CRISTINA

Ruolo: 
Tecnico - amministrativo
Telefono: 
0264488362
Stanza: 
U08, Piano: P04, Stanza: 4041
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • Fontana, D., Ramazzotti, D., Aroldi, A., Redaelli, S., Magistroni, V., Pirola, A., et al. (2020). Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HEMASPHERE, 4(6), e497 [10.1097/HS9.0000000000000497]. Dettaglio
  • Menotti, M., Ambrogio, C., Cheong, T., Pighi, C., Mota, I., Cassel, S., et al. (2019). Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. NATURE MEDICINE, 25(1), 130-140 [10.1038/s41591-018-0262-9]. Dettaglio
  • Redaelli, S., Ceccon, M., Zappa, M., Geeta, G., Mastini, C., Mauri, M., et al. (2018). Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer. CANCER RESEARCH, 78(24), 6866-6880 [10.1158/0008-5472.CAN-18-1867]. Dettaglio
  • Awad, M., Mastini, C., Patino, R., Mologni, L., Voena, C., Mussolin, L., et al. (2017). Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer. Intervento presentato a: American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA. Dettaglio
  • Awad, M., Mastini, C., Blasco, R., Mologni, L., Voena, C., Mussolin, L., et al. (2017). Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. ONCOTARGET, 8(54), 92265-92274 [10.18632/oncotarget.21182]. Dettaglio